Avantor Investor Conference Presentation Deck

Positioned for growth 1 INNOVATION 3X bioproduction revenue from NPIs¹ Specified in 85% of top 20 biologics² Collaboration agreements with Agilent, Cytovance Biologics, GeminiBio and Oxford Nanopore Navantor™ 2 24 EXPANSION Initiated 14 expansion projects³ Invested in digital architecture Achieved significant renewal and expansion milestones with top 10 customers Note: NPI New Product Introductions 1. Represents growth in total bioproduction revenues from NPIs from 2020 to 2022E. 2. 2022 data from Evaluate Pharma. 3. Manufacturing and distribution expansions in 2022. 3 M&A Integrated Masterflex, Ritter, RIM Bio Robust NPI pipeline for 2023 Actively building M&A pipeline in focus areas 8

View entire presentation